33. The Ozempic Trade: "Health" and Body Imag...

Go to groundnews.com/skinny for a better way to stay informed. Subscribe through our link for 40% off unlimited access to world-wide coverage. We're back at the intersection of AI and high finance! Anthropic is reportedly targeting a $2 trillion IPO valuation. So what did Reuters ...  Show more

Go to groundnews.com/skinny for a better way to stay informed. Subscribe through our link for 40% off unlimited access to world-wide coverage. NVIDIA just agreed to buy Hugging Face, and the deal won't add a cent to its earnings per share. So why do it? In this episode we dig int ...  Show more

Episode 601: Sam Parr ( https://twitter.com/theSamParr ) and Shaan Puri ( https://twitter.com/ShaanVP ) talk to Calley Means ( https://x.com/calleymeans ) about the $50T drug that has Americans in a chokehold.  — Show Notes: (0:00) Intro  (1:54) The problem with Ozempic (4:25) A ...  Show more

Let's dive into the rise of GLP-1 medications and what they mean for both the body and the mind. From Serena Williams stepping in as the face of Ro’s GLP-1 campaign, to Kyla’s personal weight loss journey, we explore the intersections of medicine, celebrity culture, and lived exp ...  Show more

First there was Weight Watchers, then there was Noom, and now there’s…Wegovy? Bloomberg health reporter Emma Court helps us understand the evolution of dieting programs and where they’re going next. Later, Matthew Schnier of New York Magazine and The Cut walks us through his arti ...  Show more

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ...  Show more